Uppsala, Sweden - March 26, 2026 - Double Bond Pharmaceutical AB (publ) ("DBP") announces its participation in the Karolinska Institutet (KI) Career Service Internship Program. Through this initiative, DBP will host a PhD student or Postdoctoral researcher from KI to collaborate on the advanced analysis of Real-World Evidence (RWE) for Temodex, the company's innovative treatment for glioblastoma.

Strengthening Data Precision for Temodex

The KI program is designed to bridge the gap between high-level academic research and industrial application. For DBP, this collaboration provides access to cutting-edge expertise in medical statistics and clinical methodology.

The project focuses on the analysis and validation of DBP's expanding RWE dataset, which comprises data from over 480 patients. Preliminary results already indicate a significant improvement in Overall Survival (OS) for patients treated with Temodex compared to current standard-of-care data.

Key Contributions to the RWE Analysis:

• Advanced Statistical Validation: Applying KI's rigorous academic standards to validate and ensure that the data meets the highest requirements for international publication.
• Sub-group Analysis: Identifying specific patient populations that respond most favorably to Temodex, which is crucial for future "Center of Excellence" strategies.
• Comparative Effectiveness: Benchmarking Temodex RWE against historical standard-of-care data to further strengthen the clinical value proposition for global "Compassionate Use" programs.

CEO Statement

"Collaborating with Karolinska Institutet, one of the world's leading medical universities, is a significant step for us," says Igor Lokot, CEO of Double Bond Pharmaceutical. "By integrating a high-level researcher into our team, we can apply more sophisticated analytical frameworks to our RWE dataset. This not only prepares us for our upcoming presentation at the EANS 2026 Congress in Hamburg but also solidifies the clinical evidence required to bring Temodex to the global market."

The results of this collaborative analysis are expected to be presented at the EANS 2026 Congress.

More about Career Service Internship Program: https://staff.ki.se/your-employment/careers-at-ki/company-collaboration#P302035

More about Real-World Evidence Study: https://mb.cision.com/Main/12720/4307158/3933333.pdf

More about EANS2026 Congress: https://eanscongress.org/

More about SI-053: SI-053, an enhanced reformulation of Temodex, is a locally acting formulation of temozolomide. SI-053 received Orphan Drug Designation from the European Medicines Agency in 2016 and received multiple Competent Authority and Ethics Committee approvals from 2021 to 2023 to initiate a Phase 1 clinical study.  In a proof-of-concept study with human subjects conducted in 2015, SI-053 demonstrated significant overall survival benefit when added to the standard of care for glioblastoma.  Video presentation: https://youtu.be/iweOQPq316o